EPISPOT Detection of Circulating Prostate Cells Among Adenocarcinoma Patients

The Pre-treatment Detection of Circulating, Functional, Prostate Cells Among Adenocarcinoma Patients: an Evaluation of the EPISPOT Technique

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01402154

Enrollment

361

Registered

2011-07-26

Start date

2012-01-03

Completion date

2021-03-15

Last updated

2026-06-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adenocarcinoma of the Prostate

Brief summary

The primary objective of this study is to evaluate the predictive value (in terms of remission) of a new technique for detecting circulating, functional, prostate cells among patients with localized adenocarcinoma of the prostate, and prior to any treatment.

Interventions

BIOLOGICALEPISPOT detection of the number of circulating cells

EPISPOT detection of the number of circulating, functional, prostate cells per unit blood

BIOLOGICALCellSearch detection of the number of circulating, functional, prostate cells

CellSearch detection of the number of circulating, functional, prostate cells per unit blood

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

MALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* The patient must have given his/her informed and signed consent * The patient must be insured or beneficiary of a health insurance plan * Histologically proven presence of prostate adenocarcinoma * Localized disease on digital rectal examination * Cancer without extensions * Acceptance of a curative treatment by the patient

Exclusion criteria

* The patient is participating in another study * The patient is in an exclusion period determined by a previous study * The patient is under judicial protection, under tutorship or curatorship * The patient refuses to sign the consent * It is impossible to correctly inform the patient * The patient is taking a hormone-modifying treatment * Patient taking adrogenic supplements

Design outcomes

Primary

Measure	Time frame	Description
The difference between AUCs for the EPISPOT and Cellsearch Techniques	1 day	The difference between the AUCs (area under the curve) for the EPISPOT and Cellsearch techniques for detecting functional, circulating prostate cells

Countries

France

Contacts

PRINCIPAL_INVESTIGATORStéphane Droupy, MD PhD

Centre Hospitalier Universitaire de Nīmes

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 17, 2026